Abstract
Proteins are widely used as therapeutics but often can be unstable, limiting their applications in the clinic. To improve the stability of protein drugs, synthetic polymers such as polyethylene glycol (PEG) can be covalently attached to specific protein side chains, creating protein-polymer conjugates. Though nearly thirty PEGylated proteins have been FDA-approved, our understanding is very limited of how PEG-protein interactions alter the fundamental chemical and physical properties of the conjugate.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
